MedTrace Logo

Efficacy of Fractional CO2 Laser as a Mono- or Adjuvant Therapy for Alopecia Areata

NCT04003376 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2020-05-19

No results posted yet for this study

Summary

Alopecia areata is a non-scarring hair loss disorder that affects both sexes equally. Incidence of the disease varies for different populations and in different studies, with global incidence ranging from 0.57% to 3.8%.

Etiology of alopecia areata is not completely understood, and the majority of evidence suggests that genetically predisposed individuals, when exposed to an unknown trigger, develop a predominantly autoimmune reaction, leading to acute hair loss. Environmental triggers, including viral or bacterial infections, along with autoimmune disorders, seem to play a major role in the development of alopecia areata.

Conditions

Interventions

DEVICE

fractional carbon dioxide laser alone

six sessions of fractional carbon dioxide laser will be done for alopecia areata lesions

DRUG

Triamcinolone Acetonide 10mg/mL

six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of triamcinolone acetonide

BIOLOGICAL

platelet rich plasma

six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of autologous platelet rich plasma

DRUG

vitamin D solution

six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of vitamin D solution

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Alaa Ghazally, MS · Assiut University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-26
Primary Completion
2021-07-01
Completion
2022-07-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04003376 on ClinicalTrials.gov